The treatment of B-cell lymphoma has made enormous progress during recent years, especially through the introduction of inhibitors of the B-cell receptor signaling pathway. One example is idelalisib, an inhibitor of the delta-isoform of phosphoinositol-3 kinase (PI3Kdelta), which is approved as mono-therapy for the treatment of refractory (to two prior lines of treatment) follicular lymphoma and in combination with rituximab for relapsed/refractory chronic lymphocytic leukemia (CLL) or as first line treatment in the presence of 17p deletion or TP53 mutation in patients unsuitable for chemo-immunotherapy. The new developments were reviewed in a satellite symposium at the annual meeting of the German, Austrian and Swiss societies for haematology and oncology at Basel in October 2015.
展开▼
